Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Randomized, Open-label Platform Trial Utilizing a Master Protocol to Study Novel Regimens Versus Standard of Care Treatment in NSCLC Participants

NCT06926673 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT06926673
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06926673 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Randomized, Open-label Platform Trial Utilizing a Master Protocol to Study Novel Regimens Versus Standard of Care Treatment in NSCLC Participants
Lead sponsor
GlaxoSmithKline
Phase
Phase 2
Overall status
Completed
Start date
December 23, 2021
Completion date
May 2, 2024
Enrollment
62 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

neoplasms